Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

$2.4M National Eye Institute Grant JAX for Retinal Pigment Epithelium Studies

By Jackson Laboratory | April 21, 2017

The National Eye Institute has awarded Jackson Laboratory Professor Patsy Nishina, Ph.D., and Associate Professor Gregory Carter, Ph.D., a four-year grant totaling $2,414,304 to study diseases of the retinal pigment epithelium (RPE), with the goal of identifying druggable targets for age-related macular degeneration (AMD) and other heritable retinal diseases.

The RPE is a single layer of cells lining the back of the retina that is vital to the functioning of the retinal photoreceptor cells, and thus vision itself. Nishina says, “Disruption of the RPE can lead to severe vision impairment and loss. Many heritable retinal diseases, including AMD, have origins or contributions from the RPE.”

AMD causes damage to the macula, a small spot in the central retina and the part of the eye needed for sharp, vision of objects in the light. According to the National Eye Institute, age-related macular degeneration affects more than 1.75 million Americans, a number that is expected to increase to almost 3 million by 2020 due to the aging of the U.S. population.

Currently there are no effective cures for AMD or the vast majority of RPE-related diseases. Previous studies have shown that mouse models of inherited RPE-driven disease often share similar disease features. By examining these models, which bear mutations in cell-adhesion and extracellular matrix molecules, and using computational tools that the Carter lab is developing, the research team hopes to discover some potential molecular pathways that could be druggable targets.

“Identifying druggable targets that participate during the pre-symptomatic stage of the disease is particularly important,” Nishina says, “to enable development of therapies that can prevent, delay onset or decrease the severity of RPE-associated diseases irrespective of the initial cause of the disease.”

The lab will study mouse models of inherited RPE-driven disease, collecting and analyzing extensive genetic and physiological data throughout disease progression. They will then examine other mouse models with mutations involved in cell-adhesion and extracellular matrix molecules for signs of RPE diseases. All data and mouse models from the project will be available to the research community.

Related Articles Read More >

New onesource concierge service streamlines flow cytometry management for labs
Amyloid Mass Spectrometry supports Alzheimer’s drug discovery and development
Exothera to develop and manufacture COVID vaccine based on proprietary technology
New dangers in the woods — and the hope that research offers us
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2022 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars